Lily M Wong

Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

D. Khatry, J. Cherrington, Samuel E DePrimo, 2003, BMC Cancer.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

M. Heinrich, A. Town, T. Abrams, 2003, Blood.